Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

✍ Scribed by P. D. Delmas; R. R. Recker; C. H. Chesnut; A. Skag; J. A. Stakkestad; R. Emkey; J. Gilbride; R. C. Schimmer; C. Christiansen; For the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE)

• Publisher: Springer-Verlag
• Year: 2004
• Tongue: English
• Weight: 221 KB
• Volume: 15
• Category: Article
• ISSN: 0937-941X
• DOI: 10.1007/s00198-004-1602-9